Metropolis Healthcare Q1 Results: Profit Falls, Misses Estimates
Metropolis Healthcare Ltd.'s profit fell in the first quarter of FY24, missing analysts' estimates.
The diagnostic service provider's net profit stood at Rs 29 crore in the quarter ended June, down 14% as compared with the same period in the previous fiscal, according to its exchange filing. The consensus estimate of analysts tracked by Bloomberg stood at Rs 33 crore.
Sequentially, too, it fell 14%.
Metropolis Healthcare Q1 FY24 Highlights (YoY)
Revenue declined 1% to Rs 277 crore, in line with estimates of Rs 290 crore.
Core revenue, excluding Covid and public private partnership contracts, rose 12% over last year.
Ebitda was down 8% to Rs 63 crore, against a forecast of Rs 72 crore.
Margin contracted to 22.7% from 24.5%. Analysts had projected it at 24.8%.
Shares of Metropolis Healthcare closed 0.9% lower on Wednesday, as compared with a 1.02% fall in the benchmark Sensex.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
